The Biomedical Model in Psychopathology. A Critical Historical Outline, Contemporary Context and Ethical Problems

• Authors: Stupak Radosław

Abstracts

EN

The article presents a critical historical outline and description of the biomedical model of psychopathology, focusing on the second half of the 20th century. It also identifies and discusses the key problems connected with its dominance in the contemporary clinical and research practice. These problems concern, among other things, the validity and reliability of psychiatric diagnoses, research methodology, treatment effectiveness, or the influence of pharmaceutical companies on research and therapeutic activity. The serious conceptual problems of the whole model call into question the foundations and knowledge base of contemporary psychiatry. There are also justified doubts regarding antipsychotic and antidepressant medications nowadays – despite their increasingly wide use, the number of chronically ill people keeps rising. This situation leads to serious ethical problems and warrants questions regarding the over-medicalisation of issues commonly associated with mental health. A reform of research and clinical practice is urgent.

Keywords

EN

biomedical model; bioethics; history of psychiatry; philosophy of psychiatry; psychopathology; medicalisation; pharmacotherapy; psychotherapy; schizophrenia; depression

• Publisher: Instytut Filozofii - Uniwersytet Jagielloński
• Journal: Diametros
• Year: 2020
• Volume: 17
• Issue: 66
• Pages: 18

Dates

published

2020-05

Contributors

author

Stupak Radosław

• Institute of Philosophy, Jagiellonian University in Kraków

References

• Abbasi J. (2017), Ketamine Minus the Trip: New Hope for Treatment-Resistant Depression, „JAMA” 318 (20): 1964–1966.
• Ahn R., Woodbridge A., Abraham A. et al. (2017), Financial Ties of Principal Investigators and Randomized Controlled Trial Outcomes: Cross Sectional Study, „BMJ” 356: i6770.
• American Diabetes Association (2004), Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes, „Diabetes Care” 27 (2): 596–601.
• American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders. 4th ed., „APA”, Washington, DC.
• View in Google Scholar
• Amsterdam J.D., McHenry L.B., Jureidini J.N. (2017), Zjawisko korupcji w badaniach psychia- trycznych, „Psychiatria Polska” 51 (6): 993–1008.
• Bentall R.P. (2003), Madness Explained: Psychosis and Human Nature, Penguin, London. Bernstein F. (1970), A Ten-Year History of the Early Clinical Drug Evaluation Unit (ECDEU) Program, „Psychopharmacol Bulletin” 6: 1–21.
• Bielefeldt A.Ø., Danborg P.B., Gøtzsche P.C. (2016), Precursors to Suicidality and Violence on Antidepressants: Systematic Review of Trials in Adult Healthy Volunteers, „JRSM” 109 (10): 381–392.
• Blashfield R.K., Keeley J.W., Flanagan E.H. et al. (2014), The Cycle of Classification: DSM-I Through DSM-5, „Annual Review of Clinical Psychology” 10 (1): 25–51.
• Bond C.H. (1914), The Position of Psychiatry and the Role of the General Hospitals in Its Improvement, „The Lancet” 184 (4755): 935–940.
• Bracken P., Thomas P. (2001), Postpsychiatry: A New Direction for Mental Health, „BMJ” 322 (7288): 724–727.
• Calton T., Ferriter M., Huband N. et al. (2008), A Systematic Review of the Soteria Paradigm for the Treatment of People Diagnosed with Schizophrenia, „Schizophrenia Bulletin” 34 (1): 181–192.
• Cosgrove L., Karter J.M. (2018), The Poison in the Cure: Neoliberalism and Contemporary Movements in Mental Health, „Theory & Psychology” 28 (5): 669–683.
• Cowen P.J., Browning M. (2015), What Has Serotonin to Do with Depression?, „World Psychiatry” 14 (2): 158–160.
• Davies J. (2017), How Voting and Consensus Created the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), „Anthropology & Medicine” 24 (1): 32–46.
• Davies J., Read J. (2018), A Systematic Review into the Incidence, Severity and Duration of Anti- depressant Withdrawal Effects: Are Guidelines Evidence-Based?, „Addictive Behaviors” 97 (Oct 2019): 111–121.
• de Barbaro B. (2014), Dylemat psychiatrii: „zły czy szalony”, „Psychiatra” 5 (7): 14–15.
• Deacon B.J. (2013), The Biomedical Model of Mental Disorder: A Critical Analysis of Its Validity, Utility, and Effects on Psychotherapy Research, „Clinical Psychology Review” 33: 846–861.
• Dell’Osso L., Pini S. (2012), What Did We Learn from Research on Comorbidity in Psychiatry? Advantages and Limitations in the Forthcoming DSM-V Era, „Clinical Practice and Epidemiology in Mental Health” 8: 180–184.
• Dub L.A., Lurie L.A. (1939), Use of Benzedrine in the Depressed Phase of the Psychotic State, „Ohio State Medical Journal” 35: 39–45.
• Dyga K., Stupak R. (2014), Obraz rehabilitacji psychiatrycznej w Polsce. Opis, porównania i ocena, [w:] Przepis na rehabilitację. Metodologie oraz metody w badaniach i transdyscyplinarnej praktyce rehabilitacyjnej, W. Otrębski, G. Wiącek (red.), Wydawnictwo KUL, Lublin.
• Eichenwald K., Kolata G. (1999), A Doctor’s Drug Studies Turn into Fraud, URL = https://partners.nytimes.com/library/national/science/health/051799drug-trials-industry.html [dostęp 1.08.2016].
• Ellenberger H.F. (1970), The Discovery of the Unconscious: The History and Evolution of Dynamic Psychiatry, Basic Books, New York, NY.
• Fava G.A., Offidani E. (2011), The Mechanisms of Tolerance in Antidepressant Action, „Progress in Neuro-Psychopharmacology & Biological Psychiatry” 35 (7): 1593–1602.
• U.S. Food and Drug Administration (2019), FDA Approves New Nasal Spray Medication for Treatment-Resistant Depression; Available Only at a Certified Doctor’s Office or Clinic, URL = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm632761.htm [dostęp 23.03.2019].
• Frances A.J. (2012), DSM-5 Field Trials Discredit APA, URL = https://www.psychologyto-day.com/blog/dsm5-in-distress/201210/dsm-5-field-trials-discredit-apa [dostęp
• 02.2017].
• Freemantle N., Anderson I.M., Young P. (2000), Predictive Value of Pharmacological Activity for the Relative Efficacy of Antidepressant Drugs: Meta-Regression Analysis, „The British Journal of Psychiatry” 177: 292–302.
• Gøtzsche P. (2015), Deadly Psychiatry and Organised Denial, People’s Press, Copenhagen.
• Harrow M., Jobe T.H., Faull R.N. (2012), Do All Schizophrenia Patients Need Antipsychotic Treatment Continuously Throughout Their Life Time? A 20-Year Longitudinal Study, „Psychological Medicine” 42 (10): 2145–2155.
• Harrow M., Jobe T.H., Faull R.N. et al. (2017), A 20-Year Multi-Followup Longitudinal Study Assessing Whether Antipsychotic Medications Contribute to Work Functioning in Schizophrenia, „Psychiatry Research” 256: 267–274.
• Healy D. (2002), The Creation of Psychopharmacology, Harvard University Press, Cambridge, MA.
• Hoffer A., Osmond H., Smythies J. (1954), Schizophrenia: A New Approach. II. Results of a Year’s Research, „Journal of Mental Science” 100 (418): 29–45.
• Ho B.-C., Andreasen N.C., Ziebell S. et al. (2011), Long-Term Antipsychotic Treatment and Brain Volumes: A Longitudinal Study of First-Episode Schizophrenia, „Archives of General Psychiatry” 68 (2): 128–137.
• Hollister L. (1998), From Hypertension to Psychopharmacology: A Serendipitous Career, [w:] The
• Psychopharmacologists, t. 2, D. Healy (red.), Chapman & Hall, London: 215–236.
• Huston P., Moher D. (1996), Redundancy, Disaggregation, and the Integrity of Medical Research, „Lancet” 347: 1024–1026.
• Insel T.R. (2006), Mental Illness and Brain Disease: Dispelling Myths and Promoting Recovery Through Awareness and Treatment. Subcommittee on Health of the Committee on Energy and Commerce, United States House of Representatives, URL = https://www.gpo.gov/fd-sys/pkg/CHRG-109hhrg30414/html/CHRG-109hhrg30414.htm [dostęp 10.06.2018].
• Insel T.R. (2006b), NIMH’s Dr. Thomas Insel: Group Advocacy, More Data, Will Improve Eating
• Disorders Research Funding, „Eating Disorders Review” 18: 5–6. Insel T.R. (2010), Faulty circuits, „Scientific American” 302: 44–51.
• Insel T.R. (2013), Transforming Diagnosis, URL = https://www.nimh.nih.gov/about/directors/thomasinsel/blog/2013/transforming-diagnosis.shtml [dostęp 26.01.2017].
• Jääskeläinen E., Juola P., Hirvonen N. et al. (2013), A Systematic Review and Meta-Analysis of Recovery in Schizophrenia, „Schizophrenia Bulletin” 39 (6): 1296–1306.
• Jansen K.L.R. (2004), Ketamine: Dreams and Realities, Multidisciplinary Association for Psychedelic Studies, Sarasota, FL.
• Kaczmarek E. (2018), How to Distinguish Medicalization from Over-Medicalization?, „Medicine, Health Care and Philosophy” 22 (1): 119–128
• Kamenov K., Twomey C., Cabello M. et al. (2017), The Efficacy of Psychotherapy, Pharmacotherapy and Their Combination on Functioning and Quality of Life in Depression: A Meta-Analysis, „Psychological Medicine” 47 (3): 414–425.
• Kamens S.R., Robbins B.D., Flanagan E.H. (2017), Introduction to the Special Issues on Diagnostic Alternatives, „Journal of Humanistic Psychology” 57 (6): 567–572.
• Kinderman P. (2014), A Prescription for Psychiatry, Palgrave Macmillan, Basingstoke, Hampshire. Kirkpatrick B., Buchanan R.W., Ross D.E. et al. (2001), A Separate Disease Within the Syndrome of Schizophrenia, „Archives of General Psychiatry” 58 (2): 165–171.
• Kirsch I., Deacon B.J., Huedo-Medina T.B. et al. (2008), Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration, „PLoS Med” 5 (2): e45.
• Kirsch I., Huedo-Medina T.B., Pigott H.E. et al. (2018), Do Outcomes of Clinical Trials Resemble Those “Real World” Patients? A Reanalysis of the STAR*D Antidepressant Data Set, „Psychology of Consciousness: Theory, Research, and Practice” 5 (4): 339–345.
• Krupitsky E.M., Grinenko A.Y. (1997), Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research, „Journal of Psychoactive Drugs” 29 (2): 165–183.
• Leo J. (2018), Memo to the Newest Generation of Gene Hunters: Read Jay Joseph, „Psychosis” 10 (1): 58–61.
• Longden E. (2013), The Voices in My Head. TED Talk, URL = https://www.ted.com/talks/eleanor_longden_the_voices_in_my_head?language=en [dostęp 11.08.2016].
• Ludwig A.M. (1975), The Psychiatrist as Physician, „JAMA” 234 (6): 603–604.
• Mithoefer M.C., Wagner M.T., Mithoefer A.T. et al. (2011), The Safety and Efficacy of {+/-}3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study, „Journal of Psychopharmacology” 25 (4): 439–452.
• Mithoefer M.C., Mithoefer A.T., Feduccia A.A. et al. (2018), 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial, „Lancet Psychiatry” 5 (6): 486–497.
• Moncrieff J. (2008), The Myth of the Chemical Cure, Palgrave Macmillan, Basingstoke, Hampshire.
• Moncrieff J. (2008b), Neoliberalism and Biopsychiatry: A Marriage of Convenience, [w:] Liberatory Psychiatry: Philosophy, Politics, and Mental Health, C.I. Cohen, S. Timimi (red.), Cambridge University Press, New York, NY.
• Moncrieff J., Kirsch I. (2015), Empirically Derived Criteria Cast Doubt on the Clinical Significance of Antidepressant-Placebo Differences, „Contemporary Clinical Trials” 43: 60–62.
• Moncrieff J. (2016), Misrepresenting Harms in Antidepressant Trials, „BMJ” 352: i217. Moncrieff J. (2016b), New Research into Antipsychotic Discontinuation and Reduction: The RADAR programme, URL = https://joannamoncrieff.com/2016/03/02/new-research-into-antipsychotic-discontinuation-and-reduction-the-radar-programme/ [dostęp 10.06.2018].
• Mulder R.T., Frampton C.M. (2013), Outcome of Mood Disorders Before Psychopharmacology: A Systematic Review, „Australian and New Zealand Journal of Psychiatry” 48 (3): 224–236.
• Oronowicz-Jaśkowiak W., Bąbel P. (2019), Twenty Years After ‘Listening to Prozac but Hearing Placebo’. Do We Hear Placebo Even Louder?, „Health Psychology Report” 7 (1): 1–8. Pużyński S. (2014), Czy kryzys, „Psychiatra” 5 (7): 6–8.
• Read J., Bentall R.P., Fosse R. (2009), Time to Abandon the Bio-Bio-Bio Model of Psychosis: Exploring the Epigenetic and Psychological Mechanisms by Which Adverse Life Events Lead to Psychotic Symptoms, „Epidemiology and Psychiatric Sciences” 18 (4): 299–310.
• Rees W.L., King G.N. (1952), Cortisone in the Treatment of Schizophrenia, „The Journal of Mental Science” 98: 408–413.
• Richardson T., Elliott P., Roberts R. et al. (2017), A Longitudinal Study of Financial Difficulties and Mental Health in a National Sample of British Undergraduate Students, „Community Mental Health Journal” 53 (3): 344–352.
• Rogers A., Pilgrim D. (2001), Mental Health Policy in Britain, Palgrave Macmillan, Basingstoke, Hampshire.
• Rogers D. (2017), Star Neuroscientist Tom Insel Leaves the Google-Spawned Verily for... A Startup?, URL = https://www.wired.com/2017/05/star-neuroscientist-tom-insel-leaves-google-spawned-verily-startup/ [dostęp 10.06.2018].
• Rzewuska M. (2007), Zaburzenia metaboliczne związane ze stosowaniem leków przeciwpsychotycznych u chorych na schizofrenię, „Psychiatria Polska” 41 (4): 457–472.
• Sarchet P. (2011), Harvard Scientists Disciplined for Not Declaring Ties to Drug Companies, URL = http://blogs.nature.com/news/2011/07/harvard_scientists_disciplined.html [dostęp 30.10.2018].
• Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014), Biological Insights from 108 Schizophrenia-Associated Genetic Loci, „Nature” 511 (7510): 421–427.
• Scull A. (1994), Somatic Treatments and the Historiography of Psychiatry, „Historiography of Psychiatry” 5: 1–12.
• Seikkula J., Alakare B., Aaltonen J. et al. (2006), 5 Years Experiences of First-Episode Non-Affective Psychosis in Open Dialogue Approach: Treatment Principles, Follow-Up Outcomes and Two Case Analyses, „Psychotherapy Research” 16: 214–228.
• Sharma T., Guski L.S., Freund N. et al. (2016), Suicidality and Aggression During Antidepressant Treatment: Systematic Review and Meta-Analyses Based on Clinical Study Reports, „BMJ” 352: i65.
• Shorter E. (2005), Historia psychiatrii. Od zakładu dla obłąkanych po erę Prozacu, tłum. P. Turski, Wydawnictwa Szkolne i Pedagogiczne, Warszawa.
• Smith R. (2005), Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies, „PLoS Med” 2 (5): e138.
• Spielmans G.I., Parry P.I. (2010), From Evidence-Based Medicine to Marketing-Based Medicine: Evidence from Internal Industry Documents, „Journal of Bioethical Inquiry” 7 (1): 13–29.
• Stupak R., Dobroczyński B. (2019), Projekt Soteria: zwiastun „trzeciej drogi” w psychiatrii?, „Psychiatria Polska” 53 (6): 1351–1364.
• Stupak R., Dyga K. (2018), Postpsychiatry and Postmodern Psychotherapy: Theoretical and Ethical Issues in Mental Health Care in a Polish Context, „Theory & Psychology” 28 (6): 780–799.
• Thacker P.D. (2018), Time to Act on Industry Influence Over Medicine and Lay Zombie Arguments to Rest, URL = https://blogs.bmj.com/bmj/2018/10/05/paul-d-thacker-time-to-act-on-industry-influence-over-medicine-and-lay-zombie-arguments-to-rest/ [dostęp 30.10.2018].
• The Brainstorm Consortium (2018), Analysis of Shared Heritability in Common Disorders of the Brain, „Science” 360 (6395): eaap8757.
• Varese F., Smeets F., Drukker M. et al. (2012), Childhood Adversities Increase the Risk of Psychosis: A Meta-Analysis of Patient-Control, Prospective and Cross-Sectional Cohort Studies, „Schizophrenia Bulletin” 38 (4): 661–671.
• Veling W., Susser E., van Os J. et al. (2008), Ethnic Density of Neighborhoods and Incidence of Psychotic Disorders Among Immigrants, „The American Journal of Psychiatry” 165 (1): 66–73.
• Waszkiewicz A.A., Nizio A.M. (2014), Rola psychologa klinicznego w szpitalu psychiatrycznym, „Psychiatria i Psychoterapia” 10 (1): 3–10.
• Whitaker R. (2002), Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill, Perseus Publishing, Cambridge, MA.
• Whitaker R. (2016), The Case Against Antipsychotics: A Review of Their Long-Term Effects, URL = http://www.madinamerica.com/wp-content/uploads/2016/07/The-CaseA-gainst-Antipsychotics.pdf [dostęp 10.08.2016].
• Whiteford H.A., Harris M.G., McKeon G. et al. (2013), Estimating Remission from Untreated Major Depression: A Systematic Review and Meta-Analysis, „ Psychological Medicine” 43 (8): 1569–1585.
• Wicks S., Hjern A., Dalman C. (2010), Social Risk or Genetic Liability for Psychosis? A Study of Children Born in Sweden and Reared by Adoptive Parents, „The American Journal of Psychiatry” 167 (10): 1240–1246.
• Williams J.B., Gibbon M., First M.B. et al. (1992), The Structured Clinical Interview for DSM- III-R (SCID): II. Multisite Test–Retest Reliability, „Archives of General Psychiatry” 49 (8): 630–636.
• Wolfers T., Doan N.T., Kaufmann T. et al. (2018), Mapping the Heterogeneous Phenotype of Schizophrenia and Bipolar Disorder Using Normative Models, „JAMA Psychiatry” 75 (11): 1146–1155.
• Wunderink L., Nieboer R.M., Wiersma D. et al. (2013), Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-Up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-Term Follow-Up of a 2-Year Randomized Clinical Trial, „JAMA Psychiatry” 70 (9): 913–920.
• Yesavage J.A., Fairchild J.K., Mi Z. et al. (2018), Effect of Repetitive Transcranial Magnetic Stimulation on Treatment-Resistant Major Depression in US Veterans: A Randomized Clinical Trial, „JAMA Psychiatry” 75 (9): 884–893.

Identifiers

DOI

10.33392/diam.1260

ISSN

1733-5566